Phio Pharmaceuticals (PHIO) Competitors $3.21 +0.09 (+2.88%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends PHIO vs. ADIL, BMRA, ERNA, ALZN, ORGS, MBRX, PRTG, CDIO, CELZ, and SHPHShould you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Adial Pharmaceuticals (ADIL), Biomerica (BMRA), Eterna Therapeutics (ERNA), Alzamend Neuro (ALZN), Orgenesis (ORGS), Moleculin Biotech (MBRX), Portage Biotech (PRTG), Cardio Diagnostics (CDIO), Creative Medical Technology (CELZ), and Shuttle Pharmaceuticals (SHPH). These companies are all part of the "pharmaceutical products" industry. Phio Pharmaceuticals vs. Adial Pharmaceuticals Biomerica Eterna Therapeutics Alzamend Neuro Orgenesis Moleculin Biotech Portage Biotech Cardio Diagnostics Creative Medical Technology Shuttle Pharmaceuticals Adial Pharmaceuticals (NASDAQ:ADIL) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking. Does the MarketBeat Community favor ADIL or PHIO? Adial Pharmaceuticals received 72 more outperform votes than Phio Pharmaceuticals when rated by MarketBeat users. However, 63.16% of users gave Phio Pharmaceuticals an outperform vote while only 58.06% of users gave Adial Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAdial PharmaceuticalsOutperform Votes10858.06% Underperform Votes7841.94% Phio PharmaceuticalsOutperform Votes3663.16% Underperform Votes2136.84% Do analysts prefer ADIL or PHIO? Phio Pharmaceuticals has a consensus target price of $36.00, indicating a potential upside of 1,021.50%. Given Phio Pharmaceuticals' higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Adial Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/APhio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in ADIL or PHIO? 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 5.2% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, ADIL or PHIO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$5.12MN/AN/APhio PharmaceuticalsN/AN/A-$10.83M-$19.64-0.16 Is ADIL or PHIO more profitable? Phio Pharmaceuticals' return on equity of -142.68% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -183.64% -160.59% Phio Pharmaceuticals N/A -142.68%-111.75% Does the media refer more to ADIL or PHIO? In the previous week, Adial Pharmaceuticals' average media sentiment score of 0.00 equaled Phio Pharmaceuticals'average media sentiment score. Company Overall Sentiment Adial Pharmaceuticals Neutral Phio Pharmaceuticals Neutral Which has more risk & volatility, ADIL or PHIO? Adial Pharmaceuticals has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. SummaryPhio Pharmaceuticals beats Adial Pharmaceuticals on 7 of the 10 factors compared between the two stocks. Ad Porter & CompanyThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Get Phio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHIO vs. The Competition Export to ExcelMetricPhio PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.76M$6.75B$5.04B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E Ratio-0.1612.17130.2316.67Price / SalesN/A270.431,720.2276.26Price / CashN/A46.0936.9133.54Price / Book0.175.284.604.98Net Income-$10.83M$151.33M$114.94M$224.26M7 Day Performance6.64%0.30%0.14%1.65%1 Month Performance4.22%14.88%10.15%6.92%1 Year Performance-73.18%36.87%33.87%26.46% Phio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHIOPhio Pharmaceuticals2.5715 of 5 stars$3.21+2.9%$36.00+1,021.5%-73.9%$2.76MN/A-0.168ADILAdial Pharmaceuticals0.7251 of 5 stars$1.00-2.0%N/A-55.3%$6.38MN/A0.0020Positive NewsBMRABiomerica0.9044 of 5 stars$0.37+19.4%N/A-56.7%$6.21M$5.51M-1.0360High Trading VolumeERNAEterna Therapeutics0.234 of 5 stars$1.13+2.7%N/A-20.6%$6.11M$70,000.00-0.2610Upcoming EarningsHigh Trading VolumeALZNAlzamend Neuro0.3385 of 5 stars$1.56-2.5%N/A-91.4%$6.07MN/A-1.584ORGSOrgenesis2.7306 of 5 stars$1.23+5.2%N/AN/A$5.88M$662,000.000.00150Upcoming EarningsNews CoverageGap UpMBRXMoleculin Biotech1.8857 of 5 stars$2.52-3.8%$35.00+1,288.9%-68.0%$5.83MN/A0.0020Upcoming EarningsPositive NewsPRTGPortage Biotech1.6299 of 5 stars$5.55-6.7%$120.00+2,062.2%-85.8%$5.82MN/A-0.126Positive NewsCDIOCardio Diagnostics3.0907 of 5 stars$0.25-3.8%$2.00+691.5%-30.6%$5.73M$39,138.000.007Upcoming EarningsGap DownCELZCreative Medical Technology1.2619 of 5 stars$4.23+10.4%N/A-13.5%$5.70M$17,000.00-1.045Gap UpHigh Trading VolumeSHPHShuttle Pharmaceuticals1.3318 of 5 stars$1.80flatN/AN/A$5.30MN/A-0.525Upcoming EarningsGap DownHigh Trading Volume Related Companies and Tools Related Companies ADIL Competitors BMRA Competitors ERNA Competitors ALZN Competitors ORGS Competitors MBRX Competitors PRTG Competitors CDIO Competitors CELZ Competitors SHPH Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHIO) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
